BDRX

424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "Company"), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to announce that it has partnered with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) ("Syngene") for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form. Commenting, Dan Palmer, Vice President, Technology at Biodexa said "We are delighted to be partnering with Syngene for the s

EFFECT - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

EFFECT - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

EFFECT - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

EFFECT - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

EFFECT - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

EFFECT - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

20-F - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

March 23, 2026 Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has entered into a strategic partnership with Tanner Pharma Group to make eRapa available for Familial Adenomatous Polyposis (FAP) patients via an Early Access Program and Named Patient prescribing. This initiative gives clinicians who treat FAP patients the opportunity to prescribe this investigational medicine outside of a clinical trial

3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)

6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

March 18, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") ADR Ratio Change Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts ("ADR") from one (1) ADR representing one hundred thousand (100,000) ordinary shares, to the new ratio of one (1) ADR representing five hundred thousand (500,000) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be on or about April 6, 2026. Pursuant to the Ratio Change, ADR holders will be required on a

3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)

3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)

3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)

3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)

3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)